Top Microbiome Solution Companies
pharmatechoutlook

Pharma Tech Outlook: Pharma Tech Magazine

Boston Analytical:  Spearheading Innovation in Advanced Microbiome Testing

Top 10 Microbiome Solution Companies - 2020

Both inside and out, our bodies harbor a huge array of micro-organisms. Alongside bacteria, we also host single-celled organisms known as archaea, as well as fungi, viruses and other microbes. Together these are dubbed the human microbiota. A plethora of conditions, from obesity to anxiety, appear to be linked to the microbes inside us. The human microbiome has been connected to diseases like diabetes, autism, AIDS, inflammatory bowel disease, multiple sclerosis, and cancer. Owing to this, microbiome has always been one of the hot topics of research.

Microbiomes contains 200 times more genetic material than a human genome and comprises more than 100 trillion organisms. Even to analyze a person’s gut flora can take several years. With the help of artificial intelligence (AI) and the most advanced computing hardware, however, today, the task can be reduced to minutes.

At the same time, the emergence of next-generation sequencing (NGS) has begun to challenge culture tests. Besides, healthcare professionals are also leveraging a qPCR-based platform with fluorescent-labeled oligonucleotide probes for assessing human gut microbiome composition.

Today, there is a wide variety of solution and service providers entering the industry with a set of advanced and integrated microbiome solution and service offerings. To help companies navigate through the best-of-breed microbiome solution and service providers, Pharma Tech Outlook has put together this edition. Besides, the magazine also comprises insights from thought leaders in the sector on the industry trends, best practices, recent innovations, and their advice for aspiring CIOs.

We present to you Pharma Tech Outlook’s, “Top 10 Microbiome Solution Providers – 2020.”

Top Microbiome Solution Companies

Taconic Biosciences provides the best animal solutions so that customers can acquire, custom generate, breed, precondition, test, and distribute valuable research models worldwide. Founded in 1949 by Robert Phelan, Taconic Biosciences has since grown into a global corporation with over 1,300 clients in 50 countries. Over the years, the company has played key roles in several industry-defining endeavors, including the commercialization of germ-free mice, the establishment of the International Health Monitoring System, which is the only globally harmonized health standard system in the microbiome industry, the Global Alliance For Laboratory Animal Standardization (GALAS), contract colony services, and more

www.taconic.com

4D pharma

4D pharma

4D is a world leader in the development of Live Biotherapeutics, a novel and emerging class of drugs, defined by the FDA as biological products that contain a live organism, such as a bacterium, that is applicable to the prevention, treatment or cure of a disease. 4D has developed a proprietary platform that rationally identifies novel bacteria based on a deep understanding of function and mechanism. 4D’s Live Biotherapeutic products are orally delivered single strains of bacteria that are naturally found in the healthy human gut. 4D has four clinical studies in progress, namely a Phase II clinical study of Blautix in Irritable Bowel Syndrome, a Phase I/II study of MRx0518 in combination with KEYTRUDA® (pembrolizumab) in solid tumours, a Phase I study of MRx0518 in a neoadjuvant setting for patients with solid tumours and a Phase I/II study of MRx-4DP0004 in asthma. Other focus programmes include disease areas such as CNS disease

Assembly Biosciences

Assembly Biosciences

Assembly Bio is an ambitious clinical stage biopharmaceutical company with cutting-edge therapeutics capable of improving millions of lives around the world. Our experienced and talented management team brings with them an impressive track record in the research, development and commercialization of clinically important, breakthrough therapeutics. Together they are fostering a unique culture driven by the highest standards of scientific rigor, entrepreneurial vision, and compassion for the patients whose lives we touch

Beckman Coulter

Beckman Coulter

At Beckman Coulter, we are dedicated to advancing and optimizing the laboratory. For more than 80 years, we have been a trusted partner for laboratory professionals, helping to advance scientific research and patient care. We have a vital role: our focus on innovation, reliability and efficiency has led us to become the partner of choice for clinical, research and industrial customers around the globe. In the life sciences, researchers use Beckman Coulter’s precision instruments to study complex biological problems, including causes of disease and potential new treatments. Our team of experts dedicates the time and energy to understand the complexity of research for laboratory customers in a wide variety of settings: universities, government, biotechnology and pharmaceutical companies, hospitals, and commercial laboratories. By innovating new processes and technologies, we’re challenging conventional wisdom; our goal is to develop the best, most widely trusted laboratory solutions available on the market today

BiomX

BiomX

BiomX is a microbiome company developing customized phage therapies designed to target and destroy harmful bacteria in chronic diseases such as inflammatory bowel disease (IBD) and colorectalcancer (CRC), as well as bacteria that affect the appearance of the skin. We discover and validate proprietary bacterial targets and customize our natural and engineered phage compositions against these targets. The Company’s platforms use computational and synthetic biology and cutting-edge research from Profs. Rotem Sorek, Ph.D., Eran Elinav, M.D., Ph.D., and Eran Segal, Ph.D., of The Weizmann Institute of Science; and Professor Timothy K. Lu, M.D., Ph.D., of The Massachusetts Institute of Technology

BioPlx

BioPlx

BioPlx is an advanced microbiomics company developing non-antibiotic methods for the control of infectious disease, including multiple-drug resistance “super-bugs”. The company employs targeted microbioligical agents to create unique interventional formulations. BioPlx is initially focused on control of hospital (HA) and community acquired (CA) dermal (exobiomic) disease, particularly: MRSA – (methicillin-resistant S. aureus) and MSSA (virulent – methicillin-susceptible S. aureus)

Carbiotix

Carbiotix

Carbiotix is an award-winning biotechnology company pioneering microbiome healthcare through a range of cost-effective gut health testing services and a portfolio of microbiome modulators covering prebiotic ingredients, medical foods and therapeutics. Carbiotix was founded in 2014 as a spin-off company from the Department of Biotechnology at Lund University, Sweden, the largest university in the Nordic Region and a global top 100 university. The company’s soluble fiber ingredient AXOS was selected as a top new ingredient by the Nutrition Capital Network (NCN) in Europe and the US in 2015. In 2016, an Irish-based company called Pure Fiber Limited was formed to commercialize the AXOS technology

CosmosID

CosmosID

CosmosID®, based in Rockville, Maryland, provides solutions unlocking the microbiome. A provider of Next-Generation Sequencing (NGS) Services and Bioinformatics Solutions, CosmosID focuses on microbiome analysis and the rapid identification and characterization of microorganisms for pharmaceutical R&D, molecular diagnostics, public health, food safety, agriculture, and environmental applications

Second Genome

Second Genome

Second Genome is a biopharmaceutical company with a mission to redefine disease in the context of microbiome medicine. We leverage our proprietary microbiome drug discovery and development platform to identify effective peptides, proteins and small molecule therapeutics that can address unmet medical needs

Seres Therapeutics

Seres Therapeutics

Seres Therapeutics is a clinical stage biotherapeutic company focused on discovering and developing Ecobiotic™ therapeutic products, novel drugs to treat important diseases by targeting the underlying biology of the human microbiome. Founded by Flagship VentureLabs, Seres is pioneering the first therapeutics that catalyze a shift to health by augmenting the biology of the microbiome. Current candidates span infectious, metabolic, and inflammatory diseases